Emmessar Biotech & Nutrition Ltd. Share Price & Stock Analysis

Emmessar Biotech & Nutrition Ltd. (BSE: 524768) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹14 Cr, it ranks #4,632 by market cap among the 6,197 Indian listed companies on FinBizNet, and #60 of 63 in Pharmaceuticals. At ₹26.36 (as of 16 Nov 2026), the share price is 21.0% below its 52-week high of ₹33.38 and 43.1% above its 52-week low of ₹18.42. The share price is down 12.8% over one year and up 7.9% over three months.

Key Metrics

Current Price₹26.36
Market Cap₹14 Cr
BSE Code524768
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio32.4
Return on Equity5.51%
Return on Assets1.31%
52-Week Range₹18.42 – ₹33.38
1-Year Price Change-12.8%
3-Month Price Change+7.9%
Beta (1Y)0.02
HeadquartersMumbai, Maharashtra
Websitewww.ebnl.org

Shareholding and Delivery

Delivery averaged 69.7% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).

About Emmessar Biotech & Nutrition Ltd.

Emmessar Biotech & Nutrition Limited, a healthcare company, provides healthcare and nutritional products in India and internationally. The company operates through Healthcare and Rent on Lease Land segments. It also offers CalmCream, a multi-functional skin cream; Calm Cream RESQ, a skin cream used for burns from sun, radiation, heat and chemicals; Cute-N-Comely, a cosmetic skin cream; MagiCream, a cream used for post-surgical scars; and Muscle Flex Gel, a gel used to relieve pain from aching muscles. In addition, the company offers vedaceuticals, an ayurveda disease curing medicine. Further, it provides healthcare products for dermatology, osteoporosis, anti-ageing, physical ailments, and burns, including radiation. The company was formerly known as Emmessar Chemical Industries Ltd. and changed its name to Emmessar Biotech & Nutrition Limited in April 2000. Emmessar Biotech & Nutrition Limited was incorporated in 1992 and is based in Mumbai, India.

Products and Services

1. Healthcare-This segment offers healthcare products. 2. Rent on Lease Land-This segment rents properties. 3. Others-0 4. Other Unallocable Expenditure (Net Off)-0

Business Segments

1. Rent on Leasehold Land-81.7% 2. Healthcare-18.3%

Emmessar Biotech & Nutrition Ltd. vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Emmessar Biotech & Nutrition Ltd.₹14 Cr32.45.51%—-12.8%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Emmessar Biotech & Nutrition Ltd.?

Emmessar Biotech & Nutrition Ltd. is trading at ₹26.36, with a market capitalisation of ₹14 Cr.

Which sector does Emmessar Biotech & Nutrition Ltd. belong to?

Emmessar Biotech & Nutrition Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Emmessar Biotech & Nutrition Ltd.?

Emmessar Biotech & Nutrition Ltd. has a P/E of 32.4 and a return on equity of 5.51%.

What is the stock symbol of Emmessar Biotech & Nutrition Ltd.?

Emmessar Biotech & Nutrition Ltd. is listed on the BSE under the scrip code 524768.

How has Emmessar Biotech & Nutrition Ltd.'s share price moved over the past year?

Emmessar Biotech & Nutrition Ltd.'s share price is down 12.8% over one year and up 7.9% over three months. Its 52-week range is ₹18.42 to ₹33.38.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.